Insulin-like growth factor-1 (IGF-1) levels in multiple sclerosis patients: A systematic review and meta-analysis.

Shirin YaghoobpoorMobina FathiKimia VakiliFatemeh SayehmiriMilad AlipourZahra Sadat MiriranHani GhayyemZohreh TutunchianRamtin HajibeygiZehra BatoolMoein MirzadehMohammad Hossein AghazadehMohammadreza Hajiesmaeili

Published in: PloS one (2024)

Our meta-analysis revealed no significant difference in serum levels of IGF-1, GH, IGFBP-2, and IGFBP-3 between the MS group and healthy controls, except for IGFBP1. However, our systematic review showed that the studies were controversial for IGFBP-3 serum levels. Some studies found an increase in serum level of IGFBP-3 in MS patients compared to the healthy group, while others showed a decrease.

Keyphrases

systematic review
multiple sclerosis
end stage renal disease
chronic kidney disease
ejection fraction
meta analyses
newly diagnosed
mass spectrometry
ms ms
growth hormone
randomized controlled trial
case control
binding protein
patient reported